Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
Globenewswire·2025-11-10 21:45
Initial Investment of $1 Million Received from Hexstone Capital LLC Upon ClosingMELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Trea ...